Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Liuling Jiedu Pill in preparing drugs for preventing and treating cold diseases

A technology of detoxification pills and medicines, which is applied in the direction of drug combinations, respiratory diseases, and medical raw materials derived from molluscs. It can solve problems such as dry mouth, nausea, and lethargy, and achieve the effect of expanding clinical indications

Active Publication Date: 2020-03-06
雷允上药业集团有限公司
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs are only effective in some patients and are associated with complications such as drowsiness, dry mouth and nausea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Liuling Jiedu Pill in preparing drugs for preventing and treating cold diseases
  • Application of Liuling Jiedu Pill in preparing drugs for preventing and treating cold diseases
  • Application of Liuling Jiedu Pill in preparing drugs for preventing and treating cold diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Determination of the median lethal titer (TCID 50 ) of influenza virus.

[0026] 1. Method.

[0027] Divide dog kidney cells (MDCK) into 3×10 4 cells / well, inoculated into 96-well plates, placed at 37°C, 5% CO 2 Cultivate until the monolayer grows. Add 10-fold diluted influenza virus solution, 100 μL / well, and incubate at 37°C for 2 hours; discard the supernatant, add fresh culture medium, 100 μL / well, observe the results after 2 days, and record the CPE.

[0028] Reed-Muench was used to calculate the half lethal titer (TCID 50) of the virus [refer to Reed LJ, MuenchH. Asimple method of estimating fifty percent endpoints. Am J Hyg, 1938, 27(3): 493-497].

[0029] 2. Results.

[0030] The median lethal titer of the amplified PR8 subtype influenza virus was detected to be 10 by Reed-Muench methodology 7.75 TCID50 / 0.1mL.

Embodiment 2 6

[0031] Example 2 Liuling Jiedu Pill Anti-influenza Virus Efficacy Evaluation

[0032] 1. Method.

[0033] The monolayer cells of 96-well plate were washed once with PBS, and 100 μL / well of influenza virus dilution solution containing about 100 TCID 50 was added, at 37°C, 5% CO 2 Incubate in the incubator for 2 hours, discard the virus solution, add 2-fold gradient dilution of Liuling Jiedu Pill drug, set 4 replicate wells for each concentration, take the maximum non-toxic concentration as the initial concentration of the drug, at 37°C, 5% CO 2 Incubate for 2 days in the incubator. Observe the cell lesion, stain with MTT, and measure the OD value. The half effective drug concentration (IC50) was calculated by Reed-Muench method, and the therapeutic index (SelectiveIndex, SI) was calculated: SI=TC50 / IC50). [Refer to "Pharmacological Experimental Methodology, edited by Xu Shuyun", the therapeutic index (SI)>1 means effective].

[0034] 2. Results.

[0035] The efficacy of L...

Embodiment 3

[0040] Evaluation of the protective effect of Liuling Jiedu Pill against influenza virus death in vivo.

[0041] 1. Method.

[0042] Female BALB / c mice were randomly divided into groups according to body weight. Except for the normal control group, the mice in other groups were anesthetized with ether, and the mice were given nasal drops with 2LD50 PR8 subtype virus liquid, 50 μL / mouse. The normal control group was given intranasal drops of the same volume of normal saline. The administration was started 2 hours after the intranasal infection of the virus, and the administration was continued for 5 days. Observations started from the first day of virus infection and continued for 14 days. The mental state, diet, respiration, coat color, body weight changes and death of the infected mice were observed and recorded every day.

[0043] 2. Results.

[0044] Death protection results such as figure 1 As shown, NC in the figure is the normal control group, the oseltamivir group (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention develops new efficacy and expands clinical indications of Liuling Jiedu Pill on the basis of the existing efficacy of Liuling Jiedu Pill. An in-vivo and in-vitro anti-virus and anti-inflammatory drug efficacy evaluation model is used to evaluate death protection effects of Liuling Jiedu Pill on mice infected with influenza virus and inhibition effects of Liuling Jiedu Pill on the pneumonia damage degree, the result shows that Liuling Jiedu Pill has anti-virus effects on influenza virus-induced inflammation, can regulate the immune function to exert anti-inflammatory effects, andcan be used to treat diseases such as influenza virus infection with inflammatory pneumonia and rhinitis.

Description

technical field [0001] The invention relates to the technical field of new uses of traditional Chinese medicines, in particular to the application of Liulingjiedu pills in the preparation of medicines for preventing and treating common cold diseases. Background technique [0002] Influenza (abbreviated as influenza) is an acute respiratory infection caused by influenza virus, and it is also a disease with strong contagion and fast transmission speed. Symptoms of onset are sudden onset of high fever, general pain, significant fatigue and mild respiratory symptoms. Due to the general susceptibility of the population with high mutation rate, the incidence rate is also relatively high. It has caused multiple outbreaks all over the world including China, seriously endangering human life and health. [0003] Clinical classic drugs include M2 ​​ion channel inhibitors (such as amantadine) and neuraminidase inhibitors (such as oseltamivir), but due to strong virus variability and f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/888A61P31/16A61P29/00A61P11/00A61P11/14A61P11/02A61K35/413A61K35/618
CPCA61K35/413A61K35/618A61K36/888A61P11/00A61P11/02A61P11/14A61P29/00A61P31/16A61K2300/00
Inventor 潘耀宗王恒斌张丹丹张邦国李全罗年翠戴晶晶翟云良
Owner 雷允上药业集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com